Abstract #2409

Quantification of Edema Reduction using Differential Quantitative T2 (DQT2) Mapping in Recurrent Glioblastoma Treated with Bevacizumab

Benjamin M. Ellingson¹, Timothy F. Cloughesy², Albert Lai², Phioanh L. Nghiemphu², Whitney B. Pope¹

¹Radiological Sciences, University of California Los Angeles, Los Angeles, CA, United States; ²Neurology, University of California Los Angeles, Los Angeles, CA, United States

The purpose of the current study was to quantify the reduction in T2 signal abnormality accompanying administration of the anti-angiogenic drug bevacizumab in recurrent glioblastoma (GBM) patients using a voxel-wise differential quantitative T2 (DQT2) mapping technique. Results demonstrate a significant decrease in T2 within pre-treatment T2 abnormal regions following anti-VEGF treatment. The degree of reduction in T2 was larger in patients who progress later and survive longer.